News - Business Acquisition

Quintara Biosciences announced the completion of its acquisition of Laragen Sanger Sequencing from Transnetyx, effective September 15, 2025. The move ensures uninterrupted Sanger sequencing, microbial identification, and cell line identification services for existing customers, with the same team, facilities, and pricing preserved. By expanding its footprint in Los Angeles, Quintara strengthens its California life sciences network, enhances sequencing capacity, and extends its ability to deliver comprehensive genomics solutions across the West Coast.